Investor Relations
This section of the Co-Diagnostics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Co-Diagnosticsassumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQCODX
| Beta | (1.90) |
|---|---|
| Shares Outstanding | 29.2M |
| Average Volume (10 days) | 585.6K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Buy |
|---|
| Strong Buy | 2 | |
|---|---|---|
| Buy | 0 | |
| Hold | 1 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Eugene Durenard Director | 12,500 Acquire Jan 8, 2022 |
|---|---|
James Nelson Director | 12,500 Acquire Jan 8, 2022 |
Richard S. Serbin Director | 12,500 Acquire Jan 8, 2022 |
Brian L. Brown Chief Financial Officer | 21,667 Acquire Nov 23, 2021 |
Brian L. Brown Chief Financial Officer | (6,684) Dispose Nov 23, 2021 |